HUMIRA (adalimumab) 40mg/0.8mL solution for SC inj by AbbVie AbbVie announced that the Food and Drug Administration (FDA) has approved the use of Humira (adalimumab) for moderately to severely active ...

ABBOTT PARK, Ill., Nov. 12, 2012 /PRNewswire/ -- Abbott today announced results from a post-hoc analysis of HUMIRA ® (adalimumab) data in early and long-standing moderate-to-severe rheumatoid ...

Surveyed Dermatologists Forecast Increasing Use of Stelara, Despite Lack of Long-Term Safety Data, According to a New Report from Decision Resources BURLINGTON, Mass., Sept. 22 /PRNewswire/ -- ...

AbbVie Inc. ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given an opinion in favor of expanding Humira’s label in the EU. The company’s ...

The National Institute for Health and Care Excellence is now backing the use of AbbVie's Humira on the National Health Service in England and Wales as the first approved treatment for skin condition ...

You might call it the Swiss army knife of pharmaceutical drugs. Since it hit the market in 2002 to treat rheumatoid arthritis, Humira has racked up one governmental approval after another to treat ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In 2021, Humira — the blockbuster biologic that has for ...

The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...

NORTH CHICAGO, Ill., Sept. 28, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today a global resolution of all intellectual property-related litigation with Amgen over Amgen's proposed biosimilar ...

For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (ABBV +0.59%) blockbuster immunology drug facing competition. After all, at its peak, Humira brought ...